International Assets Investment Management LLC Has $1.20 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

International Assets Investment Management LLC lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 99.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,034 shares of the biopharmaceutical company’s stock after selling 1,629,470 shares during the period. International Assets Investment Management LLC’s holdings in Gilead Sciences were worth $1,198,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of GILD. nVerses Capital LLC acquired a new stake in Gilead Sciences during the third quarter valued at $25,000. Valued Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares during the last quarter. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at approximately $33,000. Cedar Wealth Management LLC increased its holdings in Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 160 shares during the last quarter. Finally, Friedenthal Financial bought a new position in Gilead Sciences during the third quarter valued at approximately $50,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Down 1.6 %

Shares of GILD stock opened at $89.14 on Thursday. The stock has a market cap of $111.09 billion, a P/E ratio of 990.44, a price-to-earnings-growth ratio of 2.24 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The stock has a fifty day moving average price of $91.93 and a 200 day moving average price of $83.02. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period in the previous year, the business earned $2.29 EPS. The firm’s revenue was up 7.0% on a year-over-year basis. Analysts predict that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were issued a $0.77 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.46%. Gilead Sciences’s payout ratio is presently 3,422.22%.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Citigroup started coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They set a “buy” rating and a $125.00 target price on the stock. Barclays boosted their price target on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 7th. Leerink Partners raised Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $74.00 to $96.00 in a report on Monday, October 21st. Finally, Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Twelve investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $96.43.

Insider Buying and Selling

In other news, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the transaction, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares in the company, valued at $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 453,734 shares of company stock worth $41,902,086 in the last 90 days. 0.16% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.